<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02019810</url>
  </required_header>
  <id_info>
    <org_study_id>2013-003276-13</org_study_id>
    <nct_id>NCT02019810</nct_id>
  </id_info>
  <brief_title>Impact of Cardiac Blood Flow on Cerebral Blood Flow in Patients With Severe Traumatic Brain Injury</brief_title>
  <acronym>DEBITC</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe traumatic brain injury with increased intracranial pressure can lead to decreased
      cerebral blood flow. Low cerebral blood flow is responsible for secondary lesions, leading to
      bad prognosis. It is not yet established whether increasing cardiac output in these patients
      can lead to an increase in cerebral blood flow, although there are some arguments in favor of
      this hypothesis. The aim of this study is to demonstrate that increasing cardiac output will
      improve cerebral blood flow in patients with severe traumatic injury and high cerebral
      pressure.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean blood flow velocity</measure>
    <time_frame>After one hour of treatment</time_frame>
    <description>Mean blood flow velocity averaged on the two middle cerebral arteries (right and left) measured one after after the initiation of treatment. Each velocity is calculated as an average on the 10 last minutes form continuous transcranial doppler monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of brain oxygenation under treatment</measure>
    <time_frame>During one hour of treatment</time_frame>
    <description>Comparison of the brain tissue oxygenation curves (PbrO2) under treatment with and without dobutamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dobutamine doses</measure>
    <time_frame>After one hour of treatment</time_frame>
    <description>Dobutamine doses required to reach the same cerebral perfusion pressure than noradrenaline alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistivity index on renal doppler</measure>
    <time_frame>After one hour of treatment</time_frame>
    <description>Measure of resistivity index on renal doppler after one hour of treatment with and without dobutamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulsatility index on renal doppler</measure>
    <time_frame>After one hour of treatment</time_frame>
    <description>Measure of pulsatility index (PI) on renal doppler before and after one hour of treatment with and without dobutamine prediction of cerebral blood flow increase (patients with high initial renal PI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output modifications</measure>
    <time_frame>During one hour of treatment</time_frame>
    <description>Comparison of cardiac blood flow modifications under treatment for one hour with and without dobutamine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Traumatic Brain Injury With High Cerebral Pressure</condition>
  <arm_group>
    <arm_group_label>Noradrenaline alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment for 30 minutes with noradrenaline alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Noradrenaline + dobutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with noradrenaline and dobutamine for 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <arm_group_label>Noradrenaline alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dobutamine and norepinephrine</intervention_name>
    <arm_group_label>Noradrenaline + dobutamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Traumatic brain injury (TBI) with pattern of oligemia (diastolic velocity &lt;
             30cm/second and/or mean velocity &lt; 45cm/second measured with transcranial doppler or
             oxygen tissue pressure &lt; 15mmHg)

          -  Closed traumatic brain injury

          -  Isolated TBI or polytraumatism

          -  Age between 18 and 65 years old

          -  Affiliated to a social security system

        Exclusion Criteria:

          -  Instable episodes of high cerebral pressure

          -  Craniectomy

          -  High cerebral pressure without TBI

          -  No autoregulation

          -  Current hemorrhagic shock

          -  Chronic cardiac failure

          -  Chronic renal failure

          -  Hyperemia measured with transcranial doppler

          -  Short life expectancy

          -  Refused consent from the family

          -  Protected patients by the law

          -  Hypersensibility to one of the treatment or sulfites
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gilles Francony, MD</last_name>
    <phone>0033476766688</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles Francony, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Bouzat, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François Payen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Lavagne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Picard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Falcon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Christine Herault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Declety, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastien Thomas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Vinclair, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Cécile Fevre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Canet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bashar Oummahan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jerome Hanna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

